Atrial Fibrillation and Stroke in Patients with Hypertrophic Cardiomyopathy: Important New Insights

Jeffrey S. Borer; Dan Atar; Thomas Marciniak; Moo Hyun Kim; Victor Serebruany

doi:10.1055/s-0039-1678724

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2019; 119(03): 355-357
DOI: 10.1055/s-0039-1678724

Invited Editorial Focus

Georg Thieme Verlag KG Stuttgart · New York

Atrial Fibrillation and Stroke in Patients with Hypertrophic Cardiomyopathy: Important New Insights

Jeffrey S. Borer

¹The Howard Gilman Institute for Heart Valve Disease and the Schiavone Institute for Cardiovascular Research, State University of New York Downstate Medical Center, Brooklyn, New York, United States

,

Dan Atar

²Division of Medicine, Department of Cardiology B, Oslo University Hospital and Institute of Clinical Sciences, University of Oslo, Oslo, Norway

,

Thomas Marciniak

³Bethany Beach, Delaware, United States

,

Moo Hyun Kim

⁴Department of Cardiology, Dong-A University, Busan, South Korea

,

Victor Serebruany

⁵Department of Neurology, Johns Hopkins University, Baltimore, Maryland, United States

› Author Affiliations

Abstract

Full Text

References

References
1 Morrow AG, Braunwald E. Functional aortic stenosis; a malformation characterized by resistance to left ventricular outflow without anatomic obstruction. Circulation 1959; 20 (02) 181-189
2 Henry WL, Clark CE, Epstein SE. Asymmetric septal hypertrophy. Echocardiographic identification of the pathognomonic anatomic abnormality of IHSS. Circulation 1973; 47 (02) 225-233
3 Lip GYH, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: past, present and future. Thromb Haemost 2017; 117 (07) 1230-1239
4 Morrow AG, Brockenbrough EC. Surgical treatment of idiopathic hypertrophic subaortic stenosis: technic and hemodynamic results of subaortic ventriculomyotomy. Ann Surg 1961; 154: 181-189
5 Jung H, Yang PS, Sung JH. , et al. Hypertrophic cardiomyopathy in patients with atrial fibrillation: prevalence and associated stroke risks in a nationwide cohort study. Thromb Haemost 2019; 119 (02) 285-293
6 Barbut D, Borer JS, Wallerson D, Ameisen O, Lockshin M. Anticardiolipin antibody and stroke: possible relation of valvular heart disease and embolic events. Cardiology 1991; 79 (02) 99-109
7 Guttmann OP, Rahman MS, O'Mahony C, Anastasakis A, Elliott PM. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart 2014; 100 (06) 465-472
8 Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001; 104 (21) 2517-2524
9 January CT, Wann LS, Alpert JS. , et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64 (21) e1-e76
10 Kirchhof P, Benussi S, Kotecha D. , et al; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38) 2893-2962
11 Steffel J, Atar D. Non-vitamin K oral anticoagulants in ‘valvular’ atrial fibrillation: a call for action. Europace 2016; 18 (01) 1-3
12 Camm AJ, Lip GY, De Caterina R. , et al; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33 (21) 2719-2747
13 Jung H, Yang PS, Jang E. , et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation with hypertrophic cardiomyopathy: a nationwide cohort study. Chest 2018 Doi: 10.1016/j.chest.2018.11.009